GlassScriptPhysician profile
Melissa Anne Baumgardner
NPI 1063970366
$3,687.27
in general payments reported to CMS, 2019-2025
32 companies · $678 in 2025
The $678 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $491 · 2022: $638 · 2023: $1,067 · 2024: $813 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,432 · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,432.13 |
| Education | $125.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,039.55 | 2021-2025 | |
| Novo Nordisk INC | $363.55 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $325.77 | 2021-2025 | Airsupra, Breztri |
| Pfizer INC. | $287.32 | 2023-2025 | |
| Glaxosmithkline, LLC. | $228.11 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Axsome Therapeutics, INC. | $182.44 | 2022-2025 | Auvelity, Symbravo |
| Astellas Pharma US INC | $159.14 | 2023-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $139.02 | 2021-2025 | Trintellix |
| Novartis Pharmaceuticals Corporation | $92.88 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $83.38 | 2025 | Caplyta |
| Lilly USA, LLC | $78.58 | 2021-2023 | Mounjaro, Jardiance, Emgality |
| Mylan Specialty L.P. | $71.85 | 2021-2024 | Yupelri |
| Idorsia Pharmaceuticals US INC | $67.22 | 2023-2025 | Quviviq, Quviviq |
| Amgen INC. | $66.79 | 2021-2024 | Repatha, Otezla |
| Shield Therapeutics INC | $52.02 | 2022-2025 | Accrufer |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $51.04 | 2024-2025 | Rexulti |
| Viatris Specialty LLC | $40.44 | 2025 | Yupelri |
| Abbott Laboratories | $37.89 | 2024-2025 | Freestyle Libre, Freestyle Libre 3 |
| Insulet Corporation | $37.28 | 2024 | Omnipod |
| Exact Sciences Corporation | $34.16 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.54 | 2024-2025 | Jardiance |
| Gilead Sciences, INC. | $26.99 | 2024 | |
| Biogen, INC. | $25.96 | 2025 | Zurzuvae |
| Phathom Pharmaceuticals, INC. | $24.87 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $23.61 | 2023 | |
| Dexcom, INC. | $19.31 | 2021 | |
| Corcept Therapeutics | $17.86 | 2024 | Korlym |
| Medtronic, INC. | $17.68 | 2023 | Inpen Smart Insulin Delivery System |
| Merck Sharp & Dohme LLC | $17.64 | 2023 | Belsomra |
| Phadia US INC. | $15.80 | 2023 | Immunocap |
| Biohaven Pharmaceutical Holding Company LTD. | $14.32 | 2022 | |
| Avanir Pharmaceuticals, INC. | $11.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Baumgardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.